Literature DB >> 17218386

Myeloproliferative disease induced by TEL-PDGFRB displays dynamic range sensitivity to Stat5 gene dosage.

Jennifer A Cain1, Zhifu Xiang, Julie O'Neal, Friederike Kreisel, AnnaLynn Colson, Hui Luo, Lothar Hennighausen, Michael H Tomasson.   

Abstract

Expression of the constitutively activated TEL/PDGFbetaR fusion protein is associated with the t(5;12)(q33;p13) chromosomal translocation found in a subset of patients with chronic myelomonocytic leukemia. TEL/PDGFbetaR activates multiple signal transduction pathways in cell-culture systems, and expression of the TEL-PDGFRB fusion gene induces myeloproliferative disease (MPD) in mice. We used gene-targeted mice to characterize the contribution of signal transducer and activator of transcription (Stat) and Src family genes to TEL-PDGFRB-mediated transformation in methylcellulose colony and murine bone marrow transduction/transplantation assays. Fetal liver hematopoietic stem and progenitor cells harboring targeted deletion of both Stat5a and Stat5b (Stat5ab(null/null)) genes were refractory to transformation by TEL-PDGFRB in methylcellulose colony assays. Notably, these cell populations were maintained in Stat5ab(null/null) fetal livers and succumbed to transformation by c-Myc. Surprisingly, targeted disruption of either Stat5a or Stat5b alone also impaired TEL-PDGFRB-mediated transformation. Survival of TPiGFP-->Stat5a(-/-) and TPiGFP-->Stat5a(+/-) mice was significantly prolonged, demonstrating significant sensitivity of TEL-PDGFRB-induced MPD to the dosage of Stat5a. TEL-PDGFRB-mediated MPD was incompletely penetrant in TPiGFP-->Stat5b(-/-) mice. In contrast, Src family kinases Lyn, Hck, and Fgr and the Stat family member Stat1 were dispensable for TEL-PDGFRB disease. Together, these data demonstrate that Stat5a and Stat5b are dose-limiting mediators of TEL-PDGFRB-induced myeloproliferation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17218386      PMCID: PMC1874559          DOI: 10.1182/blood-2006-07-036335

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  36 in total

Review 1.  Genetics of myeloid malignancies: pathogenetic and clinical implications.

Authors:  Stefan Fröhling; Claudia Scholl; D Gary Gilliland; Ross L Levine
Journal:  J Clin Oncol       Date:  2005-09-10       Impact factor: 44.544

Review 2.  Opposing actions of STAT-1 and STAT-3.

Authors:  A Stephanou; D S Latchman
Journal:  Growth Factors       Date:  2005-09       Impact factor: 2.511

3.  Stat5a/b are essential for normal lymphoid development and differentiation.

Authors:  Zhengju Yao; Yongzhi Cui; Wendy T Watford; Jay H Bream; Kunihiro Yamaoka; Bruce D Hissong; Denise Li; Scott K Durum; Qiong Jiang; Avinash Bhandoola; Lothar Hennighausen; John J O'Shea
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-17       Impact factor: 11.205

Review 4.  The JAK2V617F tyrosine kinase mutation in myeloproliferative disorders: status report and immediate implications for disease classification and diagnosis.

Authors:  Ayalew Tefferi; D Gary Gilliland
Journal:  Mayo Clin Proc       Date:  2005-07       Impact factor: 7.616

5.  STAT activation by the PDGF receptor requires juxtamembrane phosphorylation sites but not Src tyrosine kinase activation.

Authors:  C Sachsenmaier; H B Sadowski; J A Cooper
Journal:  Oncogene       Date:  1999-06-17       Impact factor: 9.867

6.  c-Myc rapidly induces acute myeloid leukemia in mice without evidence of lymphoma-associated antiapoptotic mutations.

Authors:  Hui Luo; Qing Li; Julie O'Neal; Friederike Kreisel; Michelle M Le Beau; Michael H Tomasson
Journal:  Blood       Date:  2005-06-21       Impact factor: 22.113

7.  A single amino acid in the DNA binding regions of STAT5A and STAT5B confers distinct DNA binding specificities.

Authors:  C Boucheron; S Dumon; S C Santos; R Moriggl; L Hennighausen; S Gisselbrecht; F Gouilleux
Journal:  J Biol Chem       Date:  1998-12-18       Impact factor: 5.157

8.  Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses.

Authors:  S Teglund; C McKay; E Schuetz; J M van Deursen; D Stravopodis; D Wang; M Brown; S Bodner; G Grosveld; J N Ihle
Journal:  Cell       Date:  1998-05-29       Impact factor: 41.582

9.  Identification and characterization of a constitutively active STAT5 mutant that promotes cell proliferation.

Authors:  M Onishi; T Nosaka; K Misawa; A L Mui; D Gorman; M McMahon; A Miyajima; T Kitamura
Journal:  Mol Cell Biol       Date:  1998-07       Impact factor: 4.272

10.  Clarifying the role of Stat5 in lymphoid development and Abelson-induced transformation.

Authors:  Andrea Hoelbl; Boris Kovacic; Marc A Kerenyi; Olivia Simma; Wolfgang Warsch; Yongzhi Cui; Hartmut Beug; Lothar Hennighausen; Richard Moriggl; Veronika Sexl
Journal:  Blood       Date:  2006-02-21       Impact factor: 22.113

View more
  26 in total

1.  ETV6-PDGFRB and FIP1L1-PDGFRA stimulate human hematopoietic progenitor cell proliferation and differentiation into eosinophils: the role of nuclear factor-κB.

Authors:  Carmen P Montano-Almendras; Ahmed Essaghir; Hélène Schoemans; Inci Varis; Laura A Noël; Amélie I Velghe; Dominique Latinne; Laurent Knoops; Jean-Baptiste Demoulin
Journal:  Haematologica       Date:  2012-01-22       Impact factor: 9.941

2.  Direct activation of STAT5 by ETV6-LYN fusion protein promotes induction of myeloproliferative neoplasm with myelofibrosis.

Authors:  Yusuke Takeda; Chiaki Nakaseko; Hiroaki Tanaka; Masahiro Takeuchi; Makiko Yui; Atsunori Saraya; Satoru Miyagi; Changshan Wang; Satomi Tanaka; Chikako Ohwada; Emiko Sakaida; Naoto Yamaguchi; Koutaro Yokote; Lothar Hennighausen; Atsushi Iwama
Journal:  Br J Haematol       Date:  2011-04-15       Impact factor: 6.998

3.  Stat5 is critical for the development and maintenance of myeloproliferative neoplasm initiated by Nf1 deficiency.

Authors:  Zohar Sachs; Raha A Been; Krista J DeCoursin; Hanh T Nguyen; Nurul A Mohd Hassan; Klara E Noble-Orcutt; Craig E Eckfeldt; Emily J Pomeroy; Ernesto Diaz-Flores; Jennifer L Geurts; Miechaleen D Diers; Diane E Hasz; Kelly J Morgan; Margaret L MacMillan; Kevin M Shannon; David A Largaespada; Stephen M Wiesner
Journal:  Haematologica       Date:  2016-07-14       Impact factor: 9.941

4.  Platelet-derived growth factors and their receptors in normal and malignant hematopoiesis.

Authors:  Jean-Baptiste Demoulin; Carmen P Montano-Almendras
Journal:  Am J Blood Res       Date:  2012-01-01

5.  Multiple oligomerization domains of KANK1-PDGFRβ are required for JAK2-independent hematopoietic cell proliferation and signaling via STAT5 and ERK.

Authors:  Sandrine Medves; Laura A Noël; Carmen P Montano-Almendras; Roxana I Albu; Hélène Schoemans; Stefan N Constantinescu; Jean-Baptiste Demoulin
Journal:  Haematologica       Date:  2011-06-17       Impact factor: 9.941

Review 6.  Interpretation of cytokine signaling through the transcription factors STAT5A and STAT5B.

Authors:  Lothar Hennighausen; Gertraud W Robinson
Journal:  Genes Dev       Date:  2008-03-15       Impact factor: 11.361

7.  Csf3r mutations in mice confer a strong clonal HSC advantage via activation of Stat5.

Authors:  Fulu Liu; Ghada Kunter; Maxwell M Krem; William C Eades; Jennifer A Cain; Michael H Tomasson; Lothar Hennighausen; Daniel C Link
Journal:  J Clin Invest       Date:  2008-03       Impact factor: 14.808

8.  STAT5 requires the N-domain to maintain hematopoietic stem cell repopulating function and appropriate lymphoid-myeloid lineage output.

Authors:  Geqiang Li; Zhengqi Wang; Yi Zhang; Zizhen Kang; Eleonora Haviernikova; Yongzhi Cui; Lothar Hennighausen; Richard Moriggl; Demin Wang; William Tse; Kevin D Bunting
Journal:  Exp Hematol       Date:  2007-11       Impact factor: 3.084

9.  Tumor suppression by phospholipase C-beta3 via SHP-1-mediated dephosphorylation of Stat5.

Authors:  Wenbin Xiao; Hong Hong; Yuko Kawakami; Yuko Kato; Dianqing Wu; Hiroki Yasudo; Akiko Kimura; Hiromi Kubagawa; Luigi F Bertoli; Randall S Davis; Luan A Chau; Joaquin Madrenas; Cyrus C Hsia; Anargyros Xenocostas; Thomas J Kipps; Lothar Hennighausen; Atsushi Iwama; Hiromitsu Nakauchi; Toshiaki Kawakami
Journal:  Cancer Cell       Date:  2009-08-04       Impact factor: 31.743

10.  The fusion proteins TEL-PDGFRbeta and FIP1L1-PDGFRalpha escape ubiquitination and degradation.

Authors:  Federica Toffalini; Anders Kallin; Peter Vandenberghe; Pascal Pierre; Lucienne Michaux; Jan Cools; Jean-Baptiste Demoulin
Journal:  Haematologica       Date:  2009-08       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.